John Martin Docherty

CIK: 0001638727

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LEXX

Lexaria Bioscience Corp.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

LEXX
Lexaria Bioscience Corp.
Jul 29, 2025
Purchase(P)
Direct
5.4K shares at avg. $0.93$5K
LEXX
Lexaria Bioscience Corp.
May 15, 2025
Award(A)
Stock Options
Direct
150K shares-

		Type	Shares	Price		Ownership
Jul 29, 2025	LEXX Lexaria Bioscience Corp.	Purchase(P)	5,376	$0.93	$4,989	Direct
May 15, 2025	LEXX Lexaria Bioscience Corp.	Award(A) Stock Options	150,000	-	-	Direct

1-2 of 2 transactions

About DOCHERTY JOHN MARTIN

DOCHERTY JOHN MARTIN (SEC CIK 0001638727) files insider reports with the SEC as President of Lexaria Bioscience Corp. (LEXX).

Signal8 holds 2 ownership filings by DOCHERTY JOHN MARTIN, all Form 4s, filed between May 16, 2025 and Jul 30, 2025. Those filings report 2 transactions, from May 15, 2025 to Jul 29, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on DOCHERTY JOHN MARTIN's filings is in PORT PERRY, A6.

Recent filings by DOCHERTY JOHN MARTIN

Jul 29, 2025: Open-market purchase of LEXX shares (Form 4, code P).
May 15, 2025: Grant or award of LEXX derivative securities (Form 4, code A).

Other insiders filing for Lexaria Bioscience Corp. (LEXX)

BUNKA CHRISTOPHER, Director
Carle Vanessa, Secretary
CHRISTOPHER RICHARD, Chief Executive Officer
Shankman Michael Elliot, Chief Financial Officer
Bhullar Baljinder, Director
Baxter Nicholas W, Director

How to read Form 4 transaction codes